Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (functional) | > 32 ug ml-1 | Cytotoxic concentration of the compound against human lung fibroblast MRC-5 cells | ChEMBL. | 15633999 |
CC50 (functional) | > 32 ug ml-1 | Cytotoxic concentration of the compound against human lung fibroblast MRC-5 cells | ChEMBL. | 15633999 |
Dose (functional) | 0 mg kg-1 | Lowest dose (single subcutaneousadministration) of the compound causing >90% reduction of liveramastigotes of Leishmania infantum in mouse; Not determined | ChEMBL. | 15633999 |
IC50 (functional) | > 32 ug ml-1 | Inhibitory concentration of the compound against intracellular amastigotes of Leishmania infantum | ChEMBL. | 15633999 |
IC50 (functional) | > 32 ug ml-1 | Inhibitory concentration of the compound against intracellular amastigotes of Leishmania infantum | ChEMBL. | 15633999 |
IC90 (functional) | > 32 ug ml-1 | Inhibitory concentration of the compound against intracellular amastigotes of Leishmania infantum | ChEMBL. | 15633999 |
IC90 (functional) | > 32 ug ml-1 | Inhibitory concentration of the compound against intracellular amastigotes of Leishmania infantum | ChEMBL. | 15633999 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.